parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced in oligodendrocytes (606 nCPM)	1.00
chemistry Open Targets	a small-molecule pocket	0.60
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	6 Parkinson's papers of 241	0.74
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 11070

NALCN in dopamine neurons, braak+0.44 (p 0.240) → +0.14 (p 0.716)receipt 11079
NALCN in oligodendrocytes, braak+0.41 (p 0.277) → +0.14 (p 0.714)receipt 11078

receipt 11079: NALCN in dopamine neurons, braak

power: full sample +0.28 (p 0.258, n 18), 95% CI -0.21 to +0.66. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.26 (p 0.289, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.19 (p 0.455, n 18). could be the mix.
skeptic: leave-one-out range +0.19 to +0.43, sign flips 0; without severely affected donors +0.28 (p 0.258, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for NALCN in dopamine neurons.

case closed: nothing better to follow up.

receipt 11078: NALCN in oligodendrocytes, braak

power: full sample +0.21 (p 0.398, n 18), 95% CI -0.28 to +0.62. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.21 (p 0.398, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.21 (p 0.403, n 18). could be the mix.
skeptic: leave-one-out range +0.12 to +0.36, sign flips 0; without severely affected donors +0.21 (p 0.398, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for NALCN in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts